143268-85-3

Upstream product

• 102-92-1 Cinnamoyl chloride 
• 102-50-1 2-methyl-4-methoxyaniline 

Downstream Products

• 182572-80-1 4'-hydroxy-2'-methyl-3,3-diphenylpropionanilide 
• 143269-03-8 6-[3-(3,4-Dimethoxy-benzylamino)-2-hydroxy-propoxy]-8-methyl-1H-quinolin-2-one 
• 143268-92-2 6-[3-(Benzyl-ethyl-amino)-2-hydroxy-propoxy]-8-methyl-1H-quinolin-2-one 

Relevant academic research and scientific papers

An intermolecular Michael addition of benzene

The first intermolecular Michael addition of benzene leading to the formation of 3,3-diphenylpropionanilide is described. 2-Methoxyaniline was reacted with cinnamoyl chloride to give 2-methoxycinnamanilide (1) which was treated with aluminum chloride in b

Quinoline derivatives or salt thereof and remedy for cardiac diseases containing the same

A quinoline derivative represented by general formula (1), a medicinally acceptable salt thereof, and a remedy for cardiac diseases containing the same: STR1 [wherein ring A represents a furan, dihydrofuran or dioxolane ring, and R1 represents an aminoalkyl group]. The compound (1) has a positively inotropic effect on myocardia and an antiarrhythmic effect, and can dilate blood vessels without extremely increasing the heart rate. Therefore, a remedy for cardiac diseases containing the same as the active ingredient is remarkably useful for treating cardiac insufficiency, arrhythmia, and so forth.

Novel positive inotropic agents: Synthesis and biological activities of 6- (3-amino-2-hydroxypropoxy)-2(1H)-quinolinone derivatives

A series of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinones has been synthesized and evaluated for positive inotropic activity on the canine heart. Some of these derivatives have a potent activity with none or negative chronotropic effect in isolated, blood-perfused dog heart preparations. They also display a high selectivity for positive inotropic effect over chronotropic and vasodilatory effects in anesthetized dogs. (±)-6-[2- Hydroxy-3-[(3-methoxybenzyl)amino]propoxy]-2(1H)-quinolinone (39) and (±)-6- [3-(3,4-dimethoxybenzyl)amino]-2-hydroxypropoxy]-2(1H)-quinolinone (40) were further investigated in conscious dogs. After iv administration, they did not affect heart rate or mean blood pressure at the dose producing a 50% increase in the peak of the first derivative of the left ventricular pressure. The compounds (39, OPC-18750, and 40, OPC-18790) are the most promising agents with desirable biological activities, and now are currently undergoing clinical evaluation.